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Original Articles
Strengths and Weaknesses of a Planar Whole-Body
Method of 153Sm Dosimetry for Patients
with Metastatic Osteosarcoma and Comparison
with Three-Dimensional Dosimetry
Donika Plyku,1 David M. Loeb,1 Andrew R. Prideaux,1 Se´bastien Baechler,2
Richard L. Wahl,1,* George Sgouros,1 and Robert F. Hobbs1
Abstract
Purpose: Dosimetric accuracy depends directly upon the accuracy of the activity measurements in tumors and
organs. The authors present the methods and results of a retrospective tumor dosimetry analysis in 14 patients
with a total of 28 tumors treated with high activities of 153Sm-ethylenediaminetetramethylenephosphonate
(153Sm-EDTMP) for therapy of metastatic osteosarcoma using planar images and compare the results with
three-dimensional dosimetry.
Materials and Methods: Analysis of phantom data provided a complete set of parameters for dosimetric
calculations, including buildup factor, attenuation coefficient, and camera dead-time compensation. The latter
was obtained using a previously developed methodology that accounts for the relative motion of the camera and
patient during whole-body (WB) imaging. Tumor activity values calculated from the anterior and posterior
views of WB planar images of patients treated with 153Sm-EDTMP for pediatric osteosarcoma were compared
with the geometric mean value. The mean activities were integrated over time and tumor-absorbed doses were
calculated using the software package OLINDA/EXM.
Results: The authors found that it was necessary to employ the dead-time correction algorithm to prevent
measured tumor activity half-lives from often exceeding the physical decay half-life of 153Sm. Measured half-
lives so long are unquestionably in error. Tumor-absorbed doses varied between 0.0022 and 0.27 cGy/MBq with
an average of 0.065 cGy/MBq; however, a comparison with absorbed dose values derived from a three-
dimensional analysis for the same tumors showed no correlation; moreover, the ratio of three-dimensional
absorbed dose value to planar absorbed dose value was 2.19. From the anterior and posterior activity com-
parisons, the order of clinical uncertainty for activity and dose calculations from WB planar images, with the
present methodology, is hypothesized to be about 70%.
Conclusion: The dosimetric results from clinical patient data indicate that absolute planar dosimetry is unre-
liable and dosimetry using three-dimensional imaging is preferable, particularly for tumors, except perhaps for
the most sophisticated planar methods. The relative activity and patient kinetics derived from planar imaging
show a greater level of reliability than the dosimetry.
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Introduction
The purpose of dosimetry is to deduce dose–responserelationships for tumors and normal organs, as well as to
bring patient-based treatment planning to the clinic based on
these relationships. The accuracy and therefore the ability of
dosimetry to perform accordingly depend highly upon the
accuracy of the activity measurements in the tumors and
organs. Planar image quantification, which has long been the
principal means of activity quantification used as an input
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into the calculation of absorbed dose,1 requires an extensive
array of methodological adjustments for scatter correction,2–5
attenuation,6–8 septal penetration, and, most recently, dead-
time correction for whole-body (WB) images involving the
relative motion between the camera and imaged object,9 with
an end result that is still controversial. In particular, He
et al.10,11 showed, in the context of phantom studies, an ab-
solute uncertainty of 30% in planar quantification compared
with 5% using single-photon emission computed tomography
(SPECT) images; the relative quantification, that is, deter-
mination of kinetic parameters, is considered to be more re-
liable4,12 as the errors from scatter, septal penetration, and
attenuation generally cancel out from one time point to the
next for the same imaged object. As yet, no such comparison
has been extended to clinical data where certain methodo-
logical components present a much greater challenge and the
potential for increased uncertainty. In particular, the issue of
background subtraction becomes more problematic as the
superposition of different anatomical features with varying
uptakes and depths creates a nonuniform landscape from
which it is difficult to extract a reasonable background rate
with any accuracy, certainly not with a strictly systematic
methodology, and where ad hoc adjustments are often re-
quired to determine background rates.
Theuseof 153Sm-ethylenediaminetetramethylenephosphonate
(153Sm-EDTMP) for palliative treatment of bone metastases
from a variety of carcinomas is well established,13–16 and its
therapeutic value for patients with osteosarcoma is being
investigated.17–20 Sm-153-EDTMP, or Quadramet, is a
bone-seeking calcium mimetic containing the 153Sm radio-
nuclide, which decays by b- emission, with a half-life of 46.5
hours and a maximum b- energy of 808 keV. Sm-153 also
emits photons, including a 103 keV photon with 28.3% fre-
quency, which is used for quantitative imaging. This radio-
pharmaceutical targets new pockets of calcification such as
are seen in bony metastases from epithelial tumors and in
osteosarcoma. The calcification of new osteosarcoma lesions
is in general very rapid so that even recently established
tumors can most often be imaged and treated. Any other re-
gion of the body that has new calcification will also show
uptake of 153Sm-EDTMP, including, but not limited to, bone
that is stressed, epiphyseal growth plates, and bone that has
had recent lesions.21 This bone uptake constitutes the large
part of the background in the images. Typically, an order of
magnitudemore of uptake in bone tissue than in soft tissue can
be seen, with another order of magnitude (or more) of uptake
present in the tumor sites.
Although biodistribution and dosimetry studies of 153Sm-
EDTMP have been conducted on animals,22–24 the existing
human data are almost exclusively in patients with bone
metastases of epithelial cancers25–31 or for bone marrow
transplant32 or toxicity studies33 where the focus is not on
dosimetry, although with a few notable exceptions.17,34
In this study, the authors present the methods and results
of a retrospective planar imaging-based tumor dosimetry
analysis in 14 metastatic osteosarcoma patients treated with
153Sm-EDTMP, which complements previously published
clinical results.19,20,34,35 Because of the high activities in-
volved, camera saturation effects occur and affect quanti-
tative as well as qualitative analysis. Incorrect quantification
could lead to false half-life estimations, which would lead to
erroneous conclusions concerning the biological dynamics
of the activity distribution in the body. To account for these
effects, the authors used a previously described method for
saturation compensation in cases of relative motion between
the detector and patient.9
The main purpose of this study is to determine the reliability
of planar-based dosimetry in clinical data by comparing the
relative differences of the anterior and posterior dosimetric
values from a set of tumor data for an empiric quantification of
the uncertainty in two-dimensional dosimetry. A comparison
between two-dimensional and three-dimensional dosimetric
results (previously published34) for a set of same tumors and a
comparison of the differences in the relative uncertainties es-
timated in phantoms11,36 are also undertaken with this objec-
tive in mind. In addition, the authors will also compare
dosimetric values between the same tumors at different initial
dose values and determine the strength of the correlation be-
tween the uptakes at two different administered activities.
Materials and Methods
Patients and 153Sm-EDTMP therapy
A phase I dose-finding study of patients with high-grade
osteoblastic osteosarcoma was conducted to determine the
maximum tolerated injected activity of 153Sm-EDTMP with
hematopoietic recovery within 6 weeks. Subsequently, a phase
II study was performed to assess the safety and response of
high-risk osteosarcoma to a high injected activity of 153Sm-
EDTMP, and 11 of 14 patients who participated in the phase I
study were determined to be eligible to receive a second high
injected activity (tandem dose) of 153Sm-EDTMP. Seven of
these patients were imaged for dosimetric purposes. Loeb
et al.19,20 have described the clinical trial details and the treat-
ment plan. Briefly, patients with a positive 99mTc-methylene
diphosphonate bone scanfindingwere included in the study and
autologous hematopoietic stem cells were collected before the
first treatment with 153Sm-EDTMP (low injected activity),
which ranged from 37 to 51.8MBq/kg (1.0–1.4mCi/kg). Pa-
tients were followed up until hematologic recovery and eval-
uated for disease response. Approximately 6 weeks after the
first treatment, a second treatment (high injected activity) with
222MBq/kg (6mCi/kg) of 153Sm-EDTMP was administered.
Patients received autologous stem cell infusion 14 days after
high injected activity 153Sm-EDTMP therapy. The study was
approved by the institutional review board of Johns Hopkins
University and informed consent was provided by all patients
or their legal guardian. The data were collected from 14 met-
astatic osteosarcoma patients (ages 11–30 years, mean 18,
median 18). The patients presented with a total of 28 tumors
(mass 5 g–4 kg, mean 326 g, median 30g). More detailed pa-
tient information is given in Table 1.
Quadramet (153Sm-EDTMP) targets new pockets of cal-
cification and therefore does not, in principle, target the
earliest form of the disease, which is a soft tissue disease
which calcifies. However, the calcification is in general very
rapid so that even recently established tumors can most
often be imaged and treated. 153Sm-EDTMP can be used to
target relatively new disease, which has already accrued
mass and calcium deposit, but not disease at the cellular
level in the blood stream, for example. Any other region of
the body that has new calcification will also show uptake of
153Sm, including, but not limited to, bone that is stressed or
that has had recent lesions. This bone uptake constitutes the
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large part of the background in the images. Typically, for
the administered activity range in this study, an order of
magnitude more of uptake in bone tissue than in soft tissue
can be seen, with another order of magnitude (or more) of
uptake present in the tumor sites.
Imaging
Patients were imaged on a GE Infinia Hawkeye gamma
camera using a low-energy high-resolution collimator for the
low activity regimen and a medium-energy general-purpose
collimator for the high activity regimen, using an energy win-
dow set at 103– 10.3 keV; a sample image is shown in Figure 1.
WB scans (Fig. 1) were collected at a sweep rate of 10 cm/
minute. Since scatter windows were not set at study acquisition
time, scatter correction was performed using a buildup factor
correction term.3,37 Calibration, scatter, attenuation, and count
dead-time corrections were implemented as outlined below and
in a previous study.9
In addition, SPECT/CT imaging was done on a subset of the
patient population. This allowed for three-dimensional tumor
dosimetry using 3D-RD, a personalized dosimetry software
package.38,39 The results of that analysis have been published34
and were available for comparison with the planar dosimetry.
Dead-time correction
The counts of all the pixels in a same row are affected by
saturation in the same proportion. As illustrated in Figure 1a
and b, the measured count values were summed for each pixel
row (y values) and the corrections were made on a row-by-
row basis by applying a previously published methodology
developed for this specific purpose.9 The implementation of
this methodology requires a translation of the counts mea-
sured spatially to a time-ordered measure of counts, that is,
the counts measured as a function of time. This is necessary
as the camera dead time is a function of the activity seen by
the whole camera and thus the saturation for a specific y-row
varies as a function of time as the camera sweeps over all
positions, which include y. Thus, the activity quantification
does not depend on a single conversion, but is a function of
the activity (or count rate) itself and is incorporated into the
dead-time effect calculations. Figure 1b shows the number of
counts measured as a function of y-position, while Figure 2
shows the specifics of the modifications made to the mea-
sured counts. Figure 2a shows the number of counts measured
as a function of time, that is, related to the activity seen by the
camera at time t. The counts as a function of time (or camera
position relative to the patient) are corrected by the factor
shown in Figure 2b using a multidimensional adaptation of
Newton’s method, and the correction factor is then translated
to the spatial distribution of counts (y-row values) (Fig. 2c).
WB half-lives
A check on the correction algorithm for count rate satu-
ration was made by examining the WB clearance half-lives
Table 1. Clinical Patient and Tumor Information
Patient Sex Age Mass (kg) AA (GBq) Tumor Tumor location Tumor mass (g)
1 F 18 61.0 3.16 1 L2 vertebra 34.0
2 M 11 64.5 3.57 2 Shoulder 22.2
3 Hip 25.7
3 M 17 67.0 3.50 4 Pelvic node 5.72
4 F 30 52.0 2.37/11.5 5 Abdomen 210/379
6 Sternum 10.9/20.6
7 Chest wall n.a./18.3
8 Chest wall n.a./21.6
5 M 20 95.0 4.20 9 Shoulder 47.6
6 M 15 70.0 3.26/16.7 10 L1 vertebra 14.9
11 Femur 20.7
12 Femur 5.05
7 M 15 62.0 2.72/15.4 13 Mandible 21.2
8 F 14 46.0 1.78/9.43 14 Paraspinal 3.52/50.0
9 F 19 70.0 2.84/16.6 15 Skull 26.4
16 Left clavicle n.a./25.1




10 M 21 53.0 2.13 21 Abdomen 4130
22 Abdomen 118
11 M 12 52.0 2.39 23 Knee 633
12 M 21 76.5 3.57/17.0 24 Spine 43.2/266
25 Hip 25.1/36.3
13 M 25 100.5 3.73 26 Hip 482
14 F 25 84.5 3.93/17.8 27 Hip 65.3/1050
28 Chest n.a./17.0
When data from both low and high activity regimens are available, both are given, separated by a slash. Tumors that were not present for
the low activity regimen are designated by ‘‘n.a.’’
AA, administered activity.
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FIG. 1. Count image of a
patient (left panel). They
y-axes are the same for both
images. In the right panel, the
x-axis shows the sum of the
counts measured across the
y-row of pixels in the left
panel.
FIG. 2. Camera dead-time algorithm applied to the patient data shown in Figure 1. (a) Shows the counts seen by the
camera as a function of time as the camera passes over the patient starting from the head. (b) Shows the correction values
calculated using the algorithm as a function of time. (c) Shows the correction translated back into y-row values. Note that
the time that the camera passes over the tumor is longer than the time to travel the distance taken up by the tumor, therefore
the tumor extent is greater in the time frame (a, b) than in the physical space (c).
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obtained for each patient before and after correction for
count rate saturation. The WB effective half-time values are
given in Table 2; for comparative purposes, the authors also
present the noncorrected values. The half-life was obtained
by fitting a monoexponential fit to the WB counts at the
different time points. The WB counts were taken as the
geometric mean of the posterior and anterior counts.
Tumor dosimetry
The tumor masses and depths from the anterior and
posterior surfaces were determined from CT images ac-
quired a few days before WB planar imaging. The tumor
time–activity curves were obtained by drawing tumor re-
gions of interest (ROIs) defined by a threshold of the
maximum count value of each individual tumor on anterior
and posterior planar images, respectively, which had been
previously corrected for count saturation. A core feature of
the MIRD anteroposterior methodology of activity deter-
mination is the background subtraction. Since the activity
measured at the surface of the ROI is the sum of the con-
tribution from the tumor as well as the background activity
present in the patient both in front of and behind the tumor,
the background activity must be estimated and its contri-
bution to the ROI activity subtracted. For this, a region must
be determined where the activity is assumed to be homo-
geneously distributed as a function of patient depth and is
consistent with the background activity present at the level
of the ROI. In this methodology, the tumor region is grown
from a seed visually placed in a region of high count rate
and using a threshold determined experimentally to give an
area corresponding visually to the activity from the tumor in
question. The background region is determined graphically
by symmetry of the tumor with respect to the vertical axis,
but with a condition that there be no overlap and with a
spacing of a minimum of five voxels between the tumor and
background. Figure 3 shows an example of a tumor region
and a background region, determined using this procedure.
The counts in the tumor ROIs were scatter and attenuation
corrected using a buildup factor method,3 as implemented in
a previous publication.9 The tumor activity was then de-
termined by applying the sensitivity and dead-time con-
version and taking the geometric mean of the anteriorly and
posteriorly determined activities. The time-integrated ac-
tivity for each tumor was obtained by analytically inte-
grating a simple exponential function to the time–activity
data for each tumor. The time-integrated activity coefficient
(residence time) was then entered into the OLINDA/EXM40
tumor dose sphere module and the absorbed dose for each
tumor was obtained. Note that most patients presented with
two time points of imaging, therefore no quantitative eval-
uation of the goodness of fit was available.
A few patients also were imaged using the SPECT/CT
camera and the 3D dosimetry was performed using the 3D-
RD personalized dosimetry package.38,39 The results from
this work have been published34 and served as a comparison
for the planar dosimetry results.
Note that the size and location of the tumors are quite
diverse (Table 1). Tumors for which there was no CT im-
aging available were not taken into consideration. Neither did
the authors include tumor sites near prosthetics, which create
too much scatter in the CT and falsify the density values, as
well as make the tumor contours difficult to detect.
The average depths of the tumor from the anterior and
posterior body surfaces are also measured using these CT im-
ages. These values are then used to calculate photon attenua-
tion through the body tissue, using the buildup factor method.3
Uncertainty analysis
A first-order estimate of the uncertainty in tumor activity
calculations was obtained by comparing the estimated an-
terior and posterior activities to the value obtained by the
conjugate view method.37,41 In principle, the activity in a
tumor can be measured from a single 2D view by measuring
the counts in an ROI drawn around the tumor:
A0¼ s  CA=P  eldA=P (1)
where CA/P are the counts measured on either the anterior
(A) or posterior (P) view, respectively, in the ROI drawn
Table 2. The Nonsaturation-Corrected
Effective WB Half-Lives (meas. WB HL)
and Saturation-Corrected Effective
WB Half-Lives (corr. WB HL)

















Low and high activity data are separated by a slash.
HL, half-life; M, mean; SD, standard deviation; WB, whole-body.
FIG. 3. Count image of the tumor (right image) and
background (left image) shown in Figure 1. The background
region is determined by symmetry of the tumor with respect
to the vertical axis, but with a condition that there be no
overlap and with a spacing of a minimum of five voxels
between the tumor and background.
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around the tumor; s is the sensitivity, which converts counts
to activity; and the exponential is the factor that accounts for
attenuation, with l as the attenuation coefficient and dA/P as
the depth of the tumor seen from the anterior (A) or posterior
(P) side, respectively. The sensitivity is not applied as a
single value, but is incorporated in the dead-time saturation
curve, which gives the count rate as a function of activity.
This formulation is valid in cases where the anterior–posterior
thickness of the tumor is much smaller than the overall an-
terior–posterior thickness of the patient; otherwise, an inte-
gration of the exponential over the thickness of the tumor is
necessary. Equation (1) yields only an approximate estimate
of the tumor activity since it is valid only when there is no
activity outside of the tumor contributing to the measured
counts, which is rarely the case. In general, background
subtraction is necessary. This single formula has the disad-
vantage of requiring some three-dimensional information,
namely the depth of the tumor, usually obtained with a CT
scan; however, since it is valid for both views, the product of
the two views gives the following:
A0
2¼ s2CACP  el(dA þ dP) (2)
Since dA + dP is the thickness of the patient (D), which may
be obtained without 3D imaging, the basic equation for the
conjugate view method when the tumor is small and tumor






This approach is adopted even when three-dimensional
information is available and utilized in more sophisticated
calculations, such as including tumor self-attenuation and







where AA and AP are the activities calculated from the
counts measured in the ROI from the anterior (A) and pos-
terior (P) images, respectively. In principle, if all the ap-
propriate corrections are made, both are equal to A0. By
calculating the difference between A0 calculated from the
posterior and anterior views, an indication of the uncertainty




The relative difference between anterior and posterior




Low activity–high activity comparison
While the dosimetry based on planar imaging quantifica-
tion remains questionable, planar imaging is generally con-
sidered reliable for relative quantification. When available, a
comparison was made between the calculated absorbed doses
delivered to the same tumor for both regimens, the low ac-
tivity (1.0–1.4mCi/kg) and high activity (6.0mCi/kg), to
determine if a five-fold increase in activity results in a
comparable increase in uptake and tumor-absorbed dose.
Results
WB half-lives
A check on the correction for count rate saturation was
made by examining the WB clearance half-times obtained
for each patient before and after correction for count rate
saturation. The WB effective half-time values are given in
Table 2. The mean – standard deviation for the uncorrected
measured effective WB half-time was 45– 6 hours. The
dead-time correction model gave 42– 6 hours; these should
be compared with the physical decay half-life for 153Sm,
which is 46.5 hours. More specifically, 11 half-lives were
measured as being nonphysical (longer than 46.5 hours)
before dead-time correction, while 4 half-lives were still
nonphysical after dead-time correction.
Tumor radiation-absorbed dose
The absorbed dose values obtained using the OLINDA/
EXM homogeneous spherical model are shown in Table 3,
along with the previously published results from the three-
dimensional analysis.34
A relationship between the time-integrated activity coef-
ficient, s, and the tumor mass, m, was examined. Inspired by
the mass uptake dependency proposed by Williams et al.,42
in theory applicable to high-molecular-weight antibodies, s
was plotted against m using both the planar (Fig. 4a) and
three-dimensional uptake values (Fig. 4b). Fits of the form
of the following equation:
s¼ amb (7)
where a and b are the parameters were made to both sets
of data. The planar imaging-derived data gave a value of
a = 0.00429 h/g and b = 0.91, with a correlation coefficient of
R2 = 0.72. For the three-dimensional data from 3D-RD, the
values were a = 0.00340 h/g, b = 1.08, and R2 = 0.74.
Anteroposterior activity comparison
An assessment of the uncertainty in activity quantification
and the absorbed dose estimates was obtained by comparing
the anterior and posterior tumor activity calculations. The
standard deviation, or r value, of the percentage difference
using Equation (2) is 35.6%. A commonly used value for
uncertainty is 2r, which corresponds to a 95% confidence
interval; thus, the uncertainty on the tumor-absorbed dose
values as ascertained empirically is on the order of 71.2%.
Using Formula (3), the standard deviation is 72.5%. Both
sets of results were obtained using 99 of the 112 tumor
images (multiple time points per tumor). The remaining 13
values could not be calculated since 1 of the 2 values (an-
terior or posterior) gave completely nonsensical activity
values (could not be distinguished from the background).
3D-RD comparison
The absorbed dose values that were calculated by both
the planar and the three-dimensional methodologies were
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compared (Fig. 4c). However, only a weak correlation was
apparent (R2 = 0.44 for a linear correlation). Moreover, the
average ratio of 3D absorbed dose value to 2D absorbed
dose was 2.13– 1.22, excluding tumor No. 8, which had a
ratio of 40.9.
Low activity–high activity comparison
Ten tumors in 7 patients were imaged for both the low-dose
(*1mCi/kg) and high-dose (*6mCi/kg) regimens. A
comparison was made between the absorbed dose values. The
average ratiowas 5.29 – 2.38,which is on the order of the ratio
of activities. However, the dispersion of values is relatively
large, and by plotting the low activity absorbed dose (AD)
values versus the high-doseADvalues (Fig. 5), a linear best fit
gives a slope, m, of only 1.98 with a y-intercept of b = 6.57
with a fit value of R2 = 0.71 (blue line). Fitting the average
value gives a correlation of only R2 = 0.44 (red line). How-
ever, by omitting the outlier tumor No. 5, with a low activity/
high activity ratio of 1.69 (and with a ratio of 4.06 measured
with 3D-RD), a better correlation exists, R2 = 0.87.
Discussion
A retrospective planar imaging-based dosimetry analy-
sis was performed on osteosarcoma patients administered
153Sm-EDTMP with therapeutic intent. As suggested by
the uncorrected WB clearance half-times (Table 2), being


















1 0.417 51.9 1.91 — — — — —
2 0.630 55.2 4.40 — — — — —
3 0.566 54.9 3.42 — — — — —
4 0.0392 61.2 1.04 — — — — —
5 8.32 45.8 6.34 14.6 25.2 64.4 10.7 59.3
6 0.0674 74.2 0.95 1.48 0.861 64.4 6.47 21.9
7 — — — — 0.746 41.7 6.30 28.4
8 — — — — 0.0982 30.2 0.70 28.6
9 0.925 58.2 3.05 — — — — —
10 0.167 105.2 1.72 — 0.620 45.2 6.40 —
11 0.616 39.8 4.62 — 3.89 47.8 29.1 —
12 0.0371 44.3 1.12 — 0.304 51.8 9.14 —
13 0.244 58.0 1.78 — 1.48 48.4 10.8 —
14 0.0509 32.4 2.18 — 1.68 49.4 5.28 —
15 0.303 — 1.79 — 2.84 74.4 16.7 —
16 — — — — 0.514 43.6 3.18 2.93
17 — — — — 0.333 42.6 3.42 3.09
18 — — — — 0.218 45.8 1.44 3.13
19 — — — — 0.779 50.5 6.69 5.45
20 — — — — 0.536 47.1 2.03 3.33
21 13.4 46.8 0.54 — — — — —
22 0.846 50.0 1.14 — — — — —
23 5.59 41.4 1.44 2.06 — — — —
24 0.883 49.0 3.20 5.45 23.1 49.2 14.0 21.6
25 0.323 42.1 2.00 3.18 1.87 48.8 8.03 23.8
26 4.07 31.0 1.37 2.85 — — — —
27 0.373 37.5 0.90 1.80 2.49 — 0.39 0.79
28 — — — — 0.698 — 6.33 13.1
M 1.89 51.52 2.25 4.49 3.75 49.72 7.82 16.86
SD 3.47 16.71 1.50 4.65 7.50 10.09 6.96 17.35
The (low) index indicates the low activity results, the (high) index indicates high activity results.
AD, absorbed dose; TIA, time-integrated activity.
FIG. 4. (a) Time-integrated
activity coefficient as a function
of mass in a semilog plot using
results from the two-dimensional
analysis. The dotted line shows
the power function fit. (b) Shows
a similar fit using the data from
the 3D-RD analysis. (c) Shows
the planar absorbed dose values
as a function of the 3D-RD
absorbed dose values.
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longer than the physical half-life of 153Sm, a correction for
count saturation was required. The count dead-time cor-
rection yielded WB half-lives consistent with the physical
decay half-life of the radionuclide.
The correction method used to account for dead time, al-
though quite developed, is still a simplification of a complex
phenomenon; in particular, dead time contribution may come
from photons reaching the collimator from outside the field of
view. Similarly, the assumption that counts of all the pixels in
a same row are affected by saturation in the same proportion
is a simplification as the count rate degradation of image
quality is not uniform across the entire field of view or over
the same row. Therefore, although the data point to a rea-
sonable first-order dead-time correction, there is still ample
room for improvement of the methodology.
From an uncertainty standpoint, the comparison of the
corrected tumor activity for each view with a conjugate
view activity measure shows that the corrections applied
yielded an uncertainty of *71% for the calculated tumor
dose estimates. This is higher even than the values (30%)
found in phantom studies,11 although not surprising since
the additional complications of overlapping regions and
nonuniform background activity make quantification in
patients more complex and thus less accurate. Note that
the 71% value is an estimate from relative values used to
calculate an activity which is unknown, as opposed to the
phantom studies where the uncertainty is measured rela-
tive to a known truth. Additionally, this value is mini-
mized since in 13 of 112 instances values could not be
calculated given that either the anterior or posterior ac-
tivity value could not be determined. The comparison with
the three-dimensional results suggests an equally large
discrepancy: on average, the two-dimensional dosimetry
gave absorbed dose values more than two times lower than
the 3D-RD values.
The foregoing estimate of uncertainty should be consid-
ered when interpreting the results of any analysis using
activity quantification or dosimetry based on planar imag-
ing. For example, the reliability of the power function fit of
the tumor uptake-versus-mass data (Fig. 4a), despite a rea-
sonably high correlation coefficient, is questionable. On the
other hand, a similar fit can be seen with the 3D-RD-derived
absorbed dose values, although the values of the fitted pa-
rameters are different, which is not surprising given the lack
of correlation between the two-dimensional and three-
dimensional results (Fig. 4c). It must be noted that a strong
correlation was previously observed 34 between the ab-
sorbed dose from two distinct three-dimensional methodol-
ogies, 3D-RD and OLINDA/EXM, using activity acquired
from SPECT scans, with the differences (on the order of
5%–10%) being attributed to the lack of external contribu-
tion in the OLINDA/EXM simple sphere model. Thus, it
appears that the large discrepancies are indeed attributable
to the planar activity quantification and methodology, al-
though uncertainties are certainly present in the 3D-RD
analysis. In general, it must be stated that a lack of uncer-
tainty or error estimate attached to absorbed dose values
regardless of methodology contributes to a general skepti-
cism of dosimetry, where it becomes difficult to appreciate
the value of the results, and efforts need to be made to
establish methodologies, which will enable a systematic
presentation of dosimetric results with error bars. While
efforts are indeed underway in this direction, no general
methodology has yet been established.
The WB half-life results confirm the value of the camera
saturation algorithm as well as confirm that the relative
dosimetry is indeed more reliable than absolute quantifica-
tion for planar dosimetry, as indicated in the literature.4,12
The average measured tumor half-times are on the order of
the physical decay half-life of 46.5 hours, confirming pre-
viously published results,28 although with a much greater
variability than with the WB results. As a first approxima-
tion, the 153Sm-EDTMP binds to the tumor site such that
there is relatively little biological clearance, unlike high-
molecular-weight antibody agents, which have a more pro-
longed uptake time.43 However, the tumor half-life results
suggest some amount of tumor uptake beyond the first time
point (4 hours), although the nature of the tumor dosimetry
methodology, in particular the background subtraction,
suggests caution in this assessment.
Given the more reliable nature of the relative dosimetry,
that is, the ratio of the quantification at different time
points, the correlation between low activity and high ac-
tivity absorbed doses seems on more stable footing. In-
deed, the average ratio of 5.3 is consistent with the ratio of
administered activities and is consistent with the average
value (5.1, determined from the four tumors common to
both low activity and high activity 3D analysis) previously
determined from a different subset of patients using 3D-
RD.34 However, given the wide range of values, it seems
that individual patient uptake may vary from administra-
tion to administration possibly due to any number of pa-
tient or tumor biological factors; therefore, when using
pretherapeutic administrations to predict or plan for higher
FIG. 5. Low activity results plotted versus the high ac-
tivity results from the planar dosimetry. The solid line
shows the fit result, while the dotted line represents the
average ratio relationship.
376 PLYKU ET AL.
activity regimens, caution must be taken not to adopt a too
literal interpretation of the linear scaling and account for
individual discrepancies.
Another interpretation of the results suggests that a hybrid
method as described by He et al.,11 for example, where the
kinetics of the planar imaging are combined with the abso-
lute quantification of the 3D imaging (SPECT in this case),
would likely provide a quantification scheme with a greater
accuracy than by planar imaging alone, perhaps comparable
with 3D dosimetry. This has generally been admitted (De-
waraja et al.44) with the caveat that there are instances where
intratumoral uptake and retention vary as a function of time
and for which 3D imaging at every time point would still be
optimal.45 Moreover, the advantage of complete 3D data sets
is the ability to run Monte Carlo and score energy within
the different volumes of interest (VOIs) from all activity
within the field of view. As mentioned, Senthamizhchelvan
et al.34 have shown for a subset of this same data set that
the external dose contribution to tumors can vary up to
10% of the total dose.
As concerns the absolute quantification and the dis-
crepancies observed between the planar and 3D dosimetries,
a possible cause for this major difference could be attributed
to the particular uptake pattern and large quantities of ra-
diopharmaceutical administered. The background counts
used for subtraction tended to be high given that the patients
receive up to 400mCi of activity and that a substantial
fraction of this activity was present in the skeleton and that
often the regions of uptake included some amount of skel-
eton to be subtracted.
Recent experience in tumor dosimetry has shown that a
single absorbed dose value is unlikely to be predictive of
tumor control. Indeed, quantities that take into account tu-
mor heterogeneity such as the equivalent uniform dose are
much more likely to correlate with tumor control. This ob-
servance has a theoretical basis46 and is supported by
evidence collected in clinical studies.34,47 In addition to the
large uncertainties, planar dosimetry is unable to distinguish
activity heterogeneity and assumes uniform distribution of
activity and a homogeneous composition of the tumor.
These conditions will be met in some tumors, but, especially
for osteosarcoma, these estimates must be seen as a first-
order approximation and more accurate estimates will
require an accounting of the density and composition in-
homogeneities, as well as the nonuniformity, in absorbed
dose. For normal organs, the discrepancies may be less or
systematic, in which case planar dosimetry adapted to spe-
cific organs such as the posterior view-only approach for
kidneys may be adequate.48 Additionally, more sophisti-
cated methods of planar quantification have been developed,
which are more accurate49,50; however, they are not widely
available, nor do they resolve the issue of tumor nonuniform
uptake. Indeed, a caveat to the conclusions regarding the
levels of uncertainty in planar dosimetry is that this article
made use of a particular approach and generalizations re-
garding the exact accuracy of planar quantification should
be made with caution. Direct comparisons with this planar
activity quantification would be enlightening; however, the
artistic nature of background subtraction in patients and the
unequivocal greater uncertainties associated with phantom
planar quantification regardless of the methodology urge for
a cautious use of planar-based quantification and dosimetry.
From a clinical perspective, experience with external
radiotherapy treatment of osteosarcoma suggests that 50–70Gy
are required for this radioresistant tumor.51–53 The values
presented here are well below this threshold. Higher admin-
istered activities will yield higher absorbed doses, increasing
the likelihood of therapeutic benefit; however, considering
that a similar trial with administered activities of 30.0mCi/
kg has yet to yield significant therapeutic results,18 the effi-
cacy might be increased by combining targeted radiotherapy
for osteogenic sarcoma with other modalities in a combined
front-line treatment,54 as has been already proven effective
for myeloma.27
Conclusions
This study presents retrospective planar tumor dosimetry
results as well as an assessment of the uncertainties in tumor
activity quantification from WB planar imaging in clinical
cases of patients treated with high administered activities of
153Sm-EDTMP. Results indicate that absolute planar do-
simetry is unreliable and dosimetry using three-dimensional
imaging is preferable, particularly for tumors, except per-
haps for the most sophisticated planar methods.
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